Literature DB >> 22314326

Molecular characterization of a large MYBPC3 rearrangement in a cohort of 100 unrelated patients with hypertrophic cardiomyopathy.

V Chanavat1, M F Seronde, P Bouvagnet, P Chevalier, R Rousson, G Millat.   

Abstract

Hypertrophic cardiomyopathy (HCM), a common and clinically heterogeneous disease characterized by unexplained ventricular myocardial hypertrophy and a high risk of sudden cardiac death, is mostly caused by mutations in MYH7 and MYBPC3 genes. As 70% of MYBPC3 mutations introduce a premature termination codon, the purpose of the current study was to report the prevalence of large MYBPC3 rearrangements. A large French cohort of 100 HCM patients, for whom no putatively causative point mutations were identified previously in the most prevalent HCM-causing genes, was investigated using an MLPA methodology. One HCM patient was identified to carry a large MYBPC3 rearrangement (<1%). This patient presents a 3505-bp deletion, which begins in the intron 27 and ends 485 bp after the MYBPC3 stop codon (g.47309385_47312889del). It was originated by recombination of a 296 bp AluSz sequence located in intron 27 and a 300 bp AluSx sequence located immediately downstream of exon 35. This study allowed the characterization of the first large MYBPC3 deletion reported in the literature. However, it appears that MLPA strategy, that moderates the identification of large MYBPC3 rearrangements, might confirm a clinical diagnosis only in a small number of patients (<1%).
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314326     DOI: 10.1016/j.ejmg.2012.01.002

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

Review 1.  Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies.

Authors:  Han-Chih Hencher Lee; Chor-Kwan Ching
Journal:  Clin Biochem Rev       Date:  2019-11

2.  Molecular Diagnosis of Inherited Cardiac Diseases in the Era of Next-Generation Sequencing: A Single Center's Experience Over 5 Years.

Authors:  Alexandre Janin; Louis Januel; Cécile Cazeneuve; Antoine Delinière; Philippe Chevalier; Gilles Millat
Journal:  Mol Diagn Ther       Date:  2021-05-05       Impact factor: 4.074

3.  Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications.

Authors:  Francesca Girolami; Giulia Frisso; Matteo Benelli; Lia Crotti; Maria Iascone; Ruggiero Mango; Cristina Mazzaccara; Kalliope Pilichou; Eloisa Arbustini; Benedetta Tomberli; Giuseppe Limongelli; Cristina Basso; Iacopo Olivotto
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2018-01       Impact factor: 2.160

4.  Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy.

Authors:  Irene Mademont-Soler; Jesus Mates; Raquel Yotti; Maria Angeles Espinosa; Alexandra Pérez-Serra; Ana Isabel Fernandez-Avila; Monica Coll; Irene Méndez; Anna Iglesias; Bernat Del Olmo; Helena Riuró; Sofía Cuenca; Catarina Allegue; Oscar Campuzano; Ferran Picó; Carles Ferrer-Costa; Patricia Álvarez; Sergio Castillo; Pablo Garcia-Pavia; Esther Gonzalez-Lopez; Laura Padron-Barthe; Aranzazu Díaz de Bustamante; María Teresa Darnaude; José Ignacio González-Hevia; Josep Brugada; Francisco Fernandez-Aviles; Ramon Brugada
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

5.  ALU transposition induces familial hypertrophic cardiomyopathy.

Authors:  Landry Nfonsam; Lijia Huang; Nancy Carson; Jean McGowan-Jordan; Melanie Beaulieu Bergeron; Sharan Goobie; Susan Conacher; David McCarty; Lee Benson; Stacy Hewson; Laura Zahavich; Elizabeth Sinclair-Bourque; Amanda Smith; Ryan Potter; Mahdi Ghani; Lucas Bronicki; Olga Jarinova
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

6.  Next generation sequencing-based copy number analysis reveals low prevalence of deletions and duplications in 46 genes associated with genetic cardiomyopathies.

Authors:  Ozge Ceyhan-Birsoy; Trevor J Pugh; Mark J Bowser; Elizabeth Hynes; Ashley L Frisella; Lisa M Mahanta; Matt S Lebo; Sami S Amr; Birgit H Funke
Journal:  Mol Genet Genomic Med       Date:  2015-12-16       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.